Prevalence of Respiratory Syncytial Virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States

Value in Health

Volumn 13, Issue 1, 2010, Pages 77-86

  Krilov, Leonard R ^a,b   Palazzi, Debra L ^c   Fernandes, Ancilla W ^d   Klein, Robert W ^e   Mahadevia, Parthiv J ^d  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d MEDIMMUNE   (United States)

^e Medical Decision Modeling Inc   (United States)

Author keywords

Budget impact; Palivizumab; Premature infants; Respiratory syncytial virus; Risk factors

Indexed keywords

PALIVIZUMAB;

ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS INFECTION; RISK FACTOR; UNITED STATES; VIRUS INFECTION;

EID: 72949104157     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00586.x     Document Type: Article

References (59)

1. Centers for Disease Control, National Center of Infectious Diseases. Respiratory syncytial virus. Available from: http://www.cdc.gov/ncidod/dvrd/ revb/respiratory/rsvfeat.htm [Accessed July 30, 2009 1998 102 : 531 537. Analysis of sub-group data for preterm infants, data on file.
2. American Academy of Pediatrics. Respiratory syncytial virus. In : Pickering LK, ed. Red Book: 2006 Report of the Committee on Infectious Diseases (27th ed.). Elk Grove Village, IL : American Academy of Pediatrics, 2006.
3. Synagis [Prescribing Information Gaithersburg, MD : MedImmune, Inc., 2007.
4. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001 20 : 874 879.
5. McConnochie K, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986 140 : 806 812.
6. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004 23 : 806 814.
7. Hall C, Hall WJ, Gala CL, et al. Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr 1984 105 : 358 364.
8. Holman R, Shay DK, Curns AT, et al. Risk factors for bronchiolitis- associated deaths among infants in the United States. Pediatr Infect Dis J 2003 22 : 483 490.
9. Simoes EA, King SJ, Lehr MV, et al. Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993 147 : 303 306.
10. Lanari M, Giovannini M, Giuffré L, et al. Investigators RADAR Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 2002 33 : 458 465.
11. Cilla G, Sarasua A, Montes M, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 2006 134 : 506 513.
12. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004 23 : 815 820.
13. Holberg CJ, Wright AL, Martinez FD, et al. Child day care, smoking by caregivers, and lower respiratory tract illness in the first 3 years of life. Pediatrics 1993 91 : 885 892.
14. Anderson LJ, Parker RA, Strikas RA, et al. Day-care center attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988 82 : 300 308.
15. Wang EE, Law BJ. Respiratory syncytial virus infection in pediatric patients. Semin Pediatr Infect Dis 1998 9 : 146 153.
16. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, et al. FLIP-2 study risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008 27 : 788 793.
17. Carroll KN, Gebretsadik T, Griffin MR, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. Pediatrics 2007 119 : 1104 1112.
18. Stensballe LG, Kristensen K, Simoes EA, et al. Danish RSV Data Network. Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study. Pediatrics 2006 118 : 1360 1368.
19. Riccetto AG, Ribeiro JD, Silva MT, et al. Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks. Braz J Infect Dis 2006 10 : 357 361.
20. Rossi GA, Medici MC, Arcangeletti MC, et al. Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007 166 : 1267 1272.
21. Makari D, Mahadevia P, Li S, et al. Identifying residual risk of severe RSV disease among unprophylaxed pre-term infants. Presented at the AAP National Conference & Exhibition, October 11-14, 2008, Boston, MA. Abstract 916.
22. Simoes AE. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003 143 (Suppl. 5 S118 26.
23. Aligne CA, Stoddard JJ. Tobacco and children. An economic evaluation of the medical effects of parental smoking. Arch Pediatr Adolesc Med 1997 151 : 648 653.
24. Boezen HM, Vonk JM, van Aalderen WM, et al. Perinatal predictors of respiratory symptoms and lung function at a young adult age. Eur Respir J 2002 20 : 383 390.
25. Bradley JP, Bacharier LB, Bonfiglio J, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005 115 : e7 14.
26. Grimwood K, Cohet C, Rich FJ, et al. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect 2008 136 : 1333 1341.
27. Sampalis J, Langely J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008 28 : 471 480.
28. Centers for Disease Control. State-specific prevalence of cigarette smoking among adults and quitting among persons aged 18-35 years - United States, 2006. MMWR Morb Mortal Wkly Rep 2007 56 : 993 996.
29. Guo SS, Roche AF, Chumlea WC, et al. Growth in weight, recumbent length, and head circumference for preterm low-birthweight infants during the first three years of life using gestation-adjusted ages. Early Hum Dev 1997 47 : 305 325.
30. National Center for Health Statistics. CDC growth charts birth to 36 months. United States. Available from: http://www.cdc.gov/nchs/about/major/ nhanes/growthcharts/charts.htm [Accessed November 13, 2008 T, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003 143 : 532 540.
31. Adapted from analysis of Healthcare Costs and Utilization Project (HCUP) data. Available from: http://www.ahrq.gov/data/hcup/ [Accessed November 13, 2008 2006 55. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr55-01.pdf [Accessed November 13, 2008 2004: Analysis of birth rates for commercial population in Medical Expenditure Panel Survey (MEPS), 2004. Data on file.
32. State Health Facts. Adapted from State Health Facts. Available from: http://www.statehealthfacts.org/comparemaptable.jsp?ind=222&cat=4 [Accessed September 1, 2007 E, Tharaldson A, Peterson C, et al. Drug Trend Report, April 2008; Express Scripts, Inc. September 30, 2008 Correspondence. Data on file, 2007.
33. American Academy of Pediatrics. 2006 Pediatric Medical Cost Model. Available from: http://www.aap.org/research/pedmedcostmodel.cfm [Accessed April 2008 2007.
34. Physicians' Fee and Coding Guide 2007. A Comprehensive Fee & Coding Reference (18th ed.). Vol 1. Duluth, GA : MAG Mutual Healthcare Solutions, Inc, 2007.
35. Paramore LC, Ciuryla V, Ciesla G, et al. Economic impact of respiratory syncytial virus-related illness in the US: analysis of national databases. Pharmacoeconomics 2004 22 : 275 284.
36. Centers for Disease Control. National Vital Statistics Report 2007 56. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-06.pdf [Accessed November 13, 2008 JA, Hamilton BE, Sutton PD, et al. Division of vital statistics. Births: final data for 2002. Natl Vital Stat Rep 2003 52 : 1 113.
37. Lazaro y de Mercado P, Figueras Aloy J, Domenech Martinez E, et al. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain An Pediatr (Barc) 2006 65 : 316 324.
38. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007 25 : 55 71.
39. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006 160 : 1070 1076.
40. Lanctot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestation age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008 24 : 3223 3237.
41. Resch B, Gusenleitner W, Nuijten MJ, et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008 30 : 749 760.
42. Chirico G, Ravasio R, Sbarigia U. Cost-utility of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian J of Pediatr 2009 35 : 4. DOI:10.1186/1824-7288-35-4.
43. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics 2005 115 : 1536 1546.
44. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002 156 : 1034 1041.
45. Mahadevia PJ, Malinoski FJ. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Arch Pediatr Adolesc Med. 2007 161 : 519 520.
46. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999 354 : 541 545.
47. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005 171 : 137 141.
48. Perez-Yarza E, Moreno A, Lazaro P, et al. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007 26 : 733 739.
49. Simoes EAF, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing. J Pediatr 2007 151 : 34 42.
50. Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002 112 : 627 633.
51. National Coalition on Health Care. Health insurance costs. Facts on health insurance costs and health care. Available from: http://www.nchc.org/ facts/cost.shtml [Accessed February 25, 2009 C, Ahrens J, Fowler N. Financing end-of-life care in the USA. J R Soc Med 2001 94 : 458 461.
52. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991 133 : 1135 1151.
53. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program. Pediatrics 2004 114 : 1612 1619.
54. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999 104 : 419 427. (Pubitemid 29424659)
55. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000 22 : 1357 1369.
56. Katz BZ, Lo J, Sorrentino M. Costs of respiratory syncytial virus infection at a tertiary care children's hospital. Pharm Ther 2003 28 : 343 345.
57. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000 137 : 227 232.
58. Marchetti A, Lau H, Magar R, et al. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999 21 : 752 766.
59. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003 143 (5 Suppl. S133 41.